@artificialcelltech.com
Biotech company developing synthetic vaccines with a proprietary and patent-protected technology platform of ultra-thin multilayer polypeptide nanofilms.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Artificial Cell Technologies, Inc. (ACT) is a pioneering brand specializing in the engineering and production of multilayer nanofilm-based vaccines. Founded in 2006 in New Haven, Connecticut, ACT aims to commercialize the applications of their proprietary multilayer polypeptide nanofilm technology.
This innovative technology, developed by Dr. Donald Haynie at Louisiana Tech University, allows for the creation of nanofilms on various surfaces, including flat surfaces and round template particles. ACT has exclusively licensed this technology from Louisiana Tech University and is now focused on developing vaccines for respiratory syncytial virus (RSV) and malaria.
These vaccine candidates utilize ACT's ultra-thin multilayer polypeptide nano-films, which offer numerous advantages such as increased immunogenicity, reduced antigen dose requirements, rapid synthetic manufacture, and shelf stability at room temperature. With a strong commitment to scientific collaboration and partnerships, ACT is at the forefront of revolutionizing vaccine development and production. Contact ACT today to learn more about their groundbreaking advancements in vaccine technology
Company Type
Privately Held
Company Size
2-10
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories